Human amniotic fluid stem cell injection therapy for urethral sphincter regeneration in an animal model

BMC Medicine

Tae Gyun Kwon⁵  James J Yoo¹  Shay Soker¹  Anthony Atala¹  Ho-Yun Chung³  Jae-sung Bae⁴  Hyun Ju Lim³  Jong Kil Lee⁴  So Young Chun⁵  Bum Soo Kim² 

[1] Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA;Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea;Department of Plastic and Reconstructive Surgery, School of Medicine, Kyungpook National University, Daegu, Korea;Department of Physiology, School of Medicine, Kyungpook National University, Daegu, Korea;Joint Institute for Regenerative Medicine, Kyungpook National University Hospital, Daegu, Korea

关键词: stem cells;    amniotic fluid;    urinary incontinence;   

Others  :  857365
DOI  :  10.1186/1741-7015-10-94

 received in 2011-11-12, accepted in 2012-08-21,  发布年份 2012

【 摘 要 】

Background

Stem cell injection therapies have been proposed to overcome the limited efficacy and adverse reactions of bulking agents. However, most have significant limitations, including painful procurement, requirement for anesthesia, donor site infection and a frequently low cell yield. Recently, human amniotic fluid stem cells (hAFSCs) have been proposed as an ideal cell therapy source. In this study, we investigated whether periurethral injection of hAFSCs can restore urethral sphincter competency in a mouse model.

Methods

Amniotic fluids were collected and harvested cells were analyzed for stem cell characteristics and in vitro myogenic differentiation potency. Mice underwent bilateral pudendal nerve transection to generate a stress urinary incontinence (SUI) model and received either periurethral injection of hAFSCs, periurethral injection of Plasma-Lyte (control group), or underwent a sham (normal control group).

For in vivo cell tracking, cells were labeled with silica-coated magnetic nanoparticles containing rhodamine B isothiocyanate (MNPs@SiO2 (RITC)) and were injected into the urethral sphincter region (n = 9). Signals were detected by optical imaging. Leak point pressure and closing pressure were recorded serially after injection.

Tumorigenicity of hAFSCs was evaluated by implanting hAFSCs into the subcapsular space of the kidney, followed two weeks later by retrieval and histologic analysis.

Results

Flow activated cell sorting showed that hAFSCs expressed mesenchymal stem cell (MSC) markers, but no hematopoietic stem cell markers. Induction of myogenic differentiation in the hAFSCs resulted in expression of PAX7 and MYOD at Day 3, and DYSTROPHIN at Day 7. The nanoparticle-labeled hAFSCs could be tracked in vivo with optical imaging for up to 10 days after injection. Four weeks after injection, the mean LPP and CP were significantly increased in the hAFSC-injected group compared with the control group. Nerve regeneration and neuromuscular junction formation of injected hAFSCs in vivo was confirmed with expression of neuronal markers and acetylcholine receptor. Injection of hAFSCs caused no in vivo host CD8 lymphocyte aggregation or tumor formation.

Conclusions

hAFSCs displayed MSC characteristics and could differentiate into cells of myogenic lineage. Periurethral injection of hAFSCs into an SUI animal model restored the urethral sphincter to apparently normal histology and function, in absence of immunogenicity and tumorigenicity.

【 授权许可】

   
2012 Kim et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Deng DY: Urinary incontinence in women. Med Clin North Am 2011, 95:101-109.
• [2]Madjar S, Sharma AK, Waltzer WC, Frischer Z, Secrest CL: Periurethral mass formations following bulking agent injection for the treatment of urinary incontinence. J Urol 2006, 175:1408-1410.
• [3]Smaldone M, Chancellor MB: Muscle derived stem cell therapy for stress urinary incontinence. World J Urol 2008, 26:327-332.
• [4]Kim SO, Na HS, Kwon D, Joo S, Kim H, Ahn Y: Bone-marrow-derived mesenchymal stem cell transplantation enhances closing pressure and leak point pressure in a female urinary incontinence rat model. Urol Int 2011, 86:110-116.
• [5]Cannon TW, Lee JY, Somogyi G, Pruchnic R, Smith CP, Huard J, Chancellor MB: Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. Urology 2003, 62:958-963.
• [6]Jack GS, Almeida FG, Zhang R, Alfonso ZC, Zuk PA, RodrIGuez LV: Processed lipoaspirate cells for tissue engineering of the lower urinary tract: implications for the treatment of stress urinary incontinence and bladder reconstruction. J Urol 2005, 174:2041-2045.
• [7]De Coppi P, Bartsch G, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ: Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol 2007, 25:100-106.
• [8]Park KS, Tae J, Choi B, Kim YS, Moon C, Kim SH, Lee HS, Kim J, Kim J, Park J, Lee JH, Lee JE, Joh JW, Kim S: Characterization, in vitro cytotoxicity assessment, and in vivo visualization of multimodal, RITC-labeled, silica-coated magnetic nanoparticles for labelling human cord blood-derived mesenchymal stem cells. Nanomedicine 2010, 6:263-276.
• [9]Yoon TJ, Kim JS, Kim BG, Yu KN, Cho MH, Lee JK: Multifunctional nanoparticles possessing a "magnetic motor effect" for drug or gene delivery. Angew Chem Int Ed Engl 2005, 44:1068-1071.
• [10]Yoon TJ, Yu KN, Kim E, Kim JS, Kim BG, Yun SH, Sohn BH, Cho MH, Lee JK, Park SB: Specific targeting, cell sorting, and bioimaging with smart magnetic silica core-shell nanomaterials. Small 2006, 2:209-215.
• [11]Chermansky CJ, Cannon TW, Torimoto K, Fraser MO, Yoshimura N, de Groat WC, Chancellor MB: A model of intrinsic sphincteric deficiency in the rat: electrocauterization. Neurourol Urodyn 2004, 23:166-171.
• [12]Kakizaki H, Fraser MO, De Groat WC: Reflex pathways controlling urethral striated and smooth muscle function in the male rat. Am J Physiol 1997, 272:R1647-1656.
• [13]Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE: Chondrogenic differentiation of amniotic fluid-derived stem cells. J Mol Histol 2007, 38:405-413.
• [14]Perin L, Giuliani S, Jin D, Sedrakyan S, Carraro G, Habibian R, Warburton D, Atala A, De Filippo RE: Renal differentiation of amniotic fluid stem cells. Cell Prolif 2007, 40:936-948.
• [15]Guan X, Delo DM, Atala A, Soker S: In vitro cardiomyogenic potential of human amniotic fluid stem cells. J Tissue Eng Regen Med 2011, 5:220-228.
• [16]Antonucci I, Stuppia L, Kaneko Y, Yu S, Tajiri N, Bae EC, Chheda SH, Weinbren NL, Borlongan CV: Amniotic fluid as a rich source of mesenchymal stromal cells for transplantation therapy. Cell Transplant 2011, 20:789-795.
• [17]Benten D, Cheng K, Gupta S: Identification of transplanted human cells in animal tissues. Methods Mol Biol 2006, 326:189-201.
• [18]Yiou R, Lefaucheur JP, Atala A: The regeneration process of the striated urethral sphincter involves activation of intrinsic satellite cells. Anat Embryol 2003, 206:429-435.
• [19]Tamaki T, Uchiyama Y, Akatsuka A: Plasticity and physiological role of stem cells derived from skeletal muscle interstitium: contribution to muscle fiber hyperplasia and therapeutic use. Curr Pharm Des 2010, 16:956-967.
• [20]Delo DM, Olson J, Baptista PM, D'Agostino RB Jr, Atala A, Zhu JM, Soker S: Non-invasive longitudinal tracking of human amniotic fluid stem cells in the mouse heart. Stem Cells Dev 2008, 17:1185-1194.
• [21]Burdon TJ, Paul A, Noiseux N, Prakash S, Shum-Tim D: Bone marrow stem cell derived paracrine factors for regenerative medicine: current perspectives and therapeutic potential. Bone Marrow Res 2011, 2011:207326.
• [22]Liu CT, Yang YJ, Yin F, Wang X, Yu XH, Wang QH, Wang XL, Xie M: The immunobiological development of human bone marrow mesenchymal stem cells in the course of neuronal differentiation. Cell Immunol 2006, 244:19-32.
• [23]Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y: Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2. Tissue Eng 2007, 13:1185-1195.